Type 1 diabetes is drawing renewed global attention as diagnosis rates increase among children and young adults, placing mounting pressure on healthcare systems and family finances. Unlike lifestyle-linked metabolic disorders, Type 1 diabetes is an autoimmune condition requiring lifelong insulin therapy and continuous monitoring. Advances in glucose-sensing technology and artificial pancreas systems are transforming patient outcomes, yet affordability remains a barrier in many regions. Analysts estimate that annual treatment costs can run into several lakh rupees per patient.